JP6336899B2 - 脳血流に影響する脳損傷後の結果を改善するための脳室内ドラッグデリバリーシステム - Google Patents

脳血流に影響する脳損傷後の結果を改善するための脳室内ドラッグデリバリーシステム Download PDF

Info

Publication number
JP6336899B2
JP6336899B2 JP2014503978A JP2014503978A JP6336899B2 JP 6336899 B2 JP6336899 B2 JP 6336899B2 JP 2014503978 A JP2014503978 A JP 2014503978A JP 2014503978 A JP2014503978 A JP 2014503978A JP 6336899 B2 JP6336899 B2 JP 6336899B2
Authority
JP
Japan
Prior art keywords
therapeutic agent
calcium channel
ventricle
microparticle
cerebral
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2014503978A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014515744A (ja
JP2014515744A5 (enExample
Inventor
アール ロッホ マクドナルド
アール ロッホ マクドナルド
ブライアン エイ ロイトナー
ブライアン エイ ロイトナー
Original Assignee
エッジ セラピューティクス インコーポレイテッド
エッジ セラピューティクス インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エッジ セラピューティクス インコーポレイテッド, エッジ セラピューティクス インコーポレイテッド filed Critical エッジ セラピューティクス インコーポレイテッド
Publication of JP2014515744A publication Critical patent/JP2014515744A/ja
Publication of JP2014515744A5 publication Critical patent/JP2014515744A5/ja
Application granted granted Critical
Publication of JP6336899B2 publication Critical patent/JP6336899B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M25/00—Catheters; Hollow probes
    • A61M25/01—Introducing, guiding, advancing, emplacing or holding catheters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
    • A61M31/002—Devices for releasing a drug at a continuous and controlled rate for a prolonged period of time
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/31—Details
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Anesthesiology (AREA)
  • Inorganic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Psychology (AREA)
  • Dispersion Chemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2014503978A 2011-04-05 2012-04-05 脳血流に影響する脳損傷後の結果を改善するための脳室内ドラッグデリバリーシステム Expired - Fee Related JP6336899B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161471779P 2011-04-05 2011-04-05
US61/471,779 2011-04-05
PCT/US2012/032317 WO2012138854A1 (en) 2011-04-05 2012-04-05 Intraventricular drug delivery system for improving outcome after a brain injury affecting cerebral blood flow

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016205897A Division JP2017036320A (ja) 2011-04-05 2016-10-20 脳血流に影響する脳損傷後の結果を改善するための脳室内ドラッグデリバリーシステム

Publications (3)

Publication Number Publication Date
JP2014515744A JP2014515744A (ja) 2014-07-03
JP2014515744A5 JP2014515744A5 (enExample) 2017-01-12
JP6336899B2 true JP6336899B2 (ja) 2018-06-06

Family

ID=46969546

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2014503978A Expired - Fee Related JP6336899B2 (ja) 2011-04-05 2012-04-05 脳血流に影響する脳損傷後の結果を改善するための脳室内ドラッグデリバリーシステム
JP2016205897A Withdrawn JP2017036320A (ja) 2011-04-05 2016-10-20 脳血流に影響する脳損傷後の結果を改善するための脳室内ドラッグデリバリーシステム

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016205897A Withdrawn JP2017036320A (ja) 2011-04-05 2016-10-20 脳血流に影響する脳損傷後の結果を改善するための脳室内ドラッグデリバリーシステム

Country Status (13)

Country Link
US (2) US9364432B2 (enExample)
EP (1) EP2694133B1 (enExample)
JP (2) JP6336899B2 (enExample)
KR (1) KR20140052992A (enExample)
CN (1) CN103517726B (enExample)
AU (1) AU2012240131B2 (enExample)
CA (1) CA2832501A1 (enExample)
GB (1) GB2513675A (enExample)
HK (1) HK1198933A1 (enExample)
IL (1) IL228539B (enExample)
RU (2) RU2606169C2 (enExample)
SG (2) SG10201602665UA (enExample)
WO (1) WO2012138854A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10092524B2 (en) * 2008-06-11 2018-10-09 Edge Therapeutics, Inc. Compositions and their use to treat complications of aneurysmal subarachnoid hemorrhage
SG10201602665UA (en) * 2011-04-05 2016-05-30 Edge Therapeutics Intraventricular Drug Delivery System For Improving Outcome After A Brain Injury Affecting Cerebral Blood Flow
US9399019B2 (en) 2012-05-09 2016-07-26 Evonik Corporation Polymorph compositions, methods of making, and uses thereof
EP3682912B1 (en) * 2012-08-17 2025-11-26 AMSilk GmbH Use of self-assembling polypeptides as tissue adhesives
CN103211812A (zh) * 2013-04-02 2013-07-24 苏州大学附属第一医院 Skf96365在治疗蛛网膜下腔出血后发生的脑血管痉挛的应用
BR112019005433B1 (pt) 2016-09-20 2023-04-04 Bracco Diagnostics Inc Sistemas e técnicas para gerar, infundir e controlar distribuição de radioisótopo
US10646227B2 (en) 2016-12-29 2020-05-12 Cerepeutics, LLC Systems and methods for acute treatment to limit intracerebral hemorrhage growth
WO2019018306A1 (en) * 2017-07-17 2019-01-24 Edge Therapeutics, Inc. ADVANCED MICROPARTICULAR FORMULATIONS CONTAINING FORM 2 OF MICRONIZED POLYMORPHIC NIMODIPINE
US20190060109A1 (en) * 2017-08-31 2019-02-28 Gregory Todd Johnson Method of Preventing Traumatic Brain Injury (TBI)
EP3776598B1 (en) 2018-03-28 2022-05-04 Bracco Diagnostics Inc. Systems and techniques for calibrating radioisotope delivery systems with a gamma detector
CN112106148B (zh) 2018-03-28 2024-10-29 布拉科诊断公司 放射性同位素发生器寿命的早期检测
US12016774B2 (en) 2020-05-08 2024-06-25 Medtronic Vascular, Inc. Delivery system for prosthetic valve device having controlled release of inflow and outflow ends
RU2763254C1 (ru) * 2020-08-31 2021-12-28 Федеральное государственное бюджетное образовательное учреждение высшего образования "Волгоградский государственный медицинский университет" Министерства здравоохранения Российской Федерации ФГБОУ ВО ВолгГМУ МЗ РФ Способ лечения церебрального вазоспазма при аневризматическом субарахноидальном кровоизлиянии
US11992642B2 (en) 2020-10-30 2024-05-28 Medtronic, Inc. Implantable medical device for delivery of pharmacological agents to the deep brain structures
US11745003B2 (en) 2020-10-30 2023-09-05 Medtronic, Inc. Implantable access port with one-directional filter
US11931545B2 (en) 2020-10-30 2024-03-19 Medtronic, Inc. Drug infusion port
US12226609B2 (en) 2020-12-16 2025-02-18 Medtronic, Inc. Method to detect inadvertent delivery of drug to a subcutaneous pocket

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4757128A (en) 1986-08-01 1988-07-12 Massachusetts Institute Of Technology High molecular weight polyanhydride and preparation thereof
ATE133087T1 (de) 1989-05-04 1996-02-15 Southern Res Inst Einkapselungsverfahren
US5650489A (en) 1990-07-02 1997-07-22 The Arizona Board Of Regents Random bio-oligomer library, a method of synthesis thereof, and a method of use thereof
IT1243390B (it) 1990-11-22 1994-06-10 Vectorpharma Int Composizioni farmaceutiche in forma di particelle atte al rilascio controllato di sostanze farmacologicamente attive e procedimento per la loro preparazione.
US5399665A (en) 1992-11-05 1995-03-21 Massachusetts Institute Of Technology Biodegradable polymers for cell transplantation
EP0740791A4 (en) 1994-01-05 2000-04-05 Arqule Inc SYSTEMATIC MODULAR PRODUCTION OF AMINIMID AND OXAZOLONE-BASED MOLECULES WITH SELECTED PROPERTIES
US5712171A (en) 1995-01-20 1998-01-27 Arqule, Inc. Method of generating a plurality of chemical compounds in a spatially arranged array
US5747058A (en) 1995-06-07 1998-05-05 Southern Biosystems, Inc. High viscosity liquid controlled delivery system
US5968542A (en) 1995-06-07 1999-10-19 Southern Biosystems, Inc. High viscosity liquid controlled delivery system as a device
AT404429B (de) 1995-06-09 1998-11-25 Immuno Ag Anti-plasma-antikörper-präparation
JP2909418B2 (ja) 1995-09-18 1999-06-23 株式会社資生堂 薬物の遅延放出型マイクロスフイア
EP0932399B1 (en) 1996-03-12 2006-01-04 PG-TXL Company, L.P. Water soluble paclitaxel prodrugs
WO1998027963A2 (en) * 1996-12-20 1998-07-02 Alza Corporation Gel composition and methods
US6123956A (en) * 1997-07-10 2000-09-26 Keith Baker Methods for universally distributing therapeutic agents to the brain
WO1999018949A1 (en) * 1997-10-15 1999-04-22 Thomas Jefferson University Nitric oxide donor compositions, methods, apparatus, and kits for preventing or alleviating vasoconstriction or vasospasm in a mammal
JP2000070366A (ja) * 1998-09-02 2000-03-07 Arute:Kk 容器兼用注射器及び容器兼用注射器への凍結乾燥製剤の封入方法
CA2396016A1 (en) * 1999-12-29 2001-07-05 Andy Bernhardt System for reconstituting pastes and methods of using same
EP1250166B1 (en) 2000-01-25 2010-03-17 Edwards Lifesciences Corporation Delivery systems for treatment of restenosis and anastomotic intimal hyperplasia
AU2002335658A1 (en) * 2001-08-31 2003-03-18 Neuron Therapeutics, Inc. Treatment of neurologic hemorrhage
US20040235801A1 (en) 2001-10-25 2004-11-25 Jean-Pierre Julien Therapy for stroke
EP1459727B1 (en) 2001-11-22 2010-06-09 Japan Science and Technology Agency Nonhuman model animal unresponsive to immunopotentiating synthetic compound
JP2005524657A (ja) 2002-02-27 2005-08-18 ファーメイン， エルティーディー． 治療剤及び他の物質を送達するための組成物、及び、前記組成物を作製し使用する方法
TW200307011A (en) * 2002-04-18 2003-12-01 Chugai Pharmaceutical Co Ltd Hyaluronic acid modifier
CN1665925A (zh) 2002-04-30 2005-09-07 马克西根控股公司 凝血因子Ⅶ或Ⅶa多肽变体
CN1671400A (zh) 2002-07-03 2005-09-21 派瑞克科学公司 透明质酸组合物以及使用方法
DK1553927T3 (da) 2002-09-11 2011-01-31 Elan Pharma Int Ltd Gel-stabiliserede, nanopartikulære aktivstof-sammensætninger
JP4092994B2 (ja) * 2002-09-13 2008-05-28 ニプロ株式会社 プレフィルドシリンジキット
WO2004047768A2 (en) 2002-11-26 2004-06-10 Seacoast Neuroscience, Inc. Buoyant polymer particles delivering therapeutic agents
US20070207211A1 (en) 2003-04-10 2007-09-06 Pr Pharmaceuticals, Inc. Emulsion-based microparticles and methods for the production thereof
JP2007515392A (ja) 2003-04-10 2007-06-14 ピーアール ファーマシューティカルズ，インコーポレイテッド エマルジョンベースの微粒子の製造のための方法
CA2533592C (en) 2003-07-23 2015-11-10 Pr Pharmaceuticals, Inc. Controlled release compositions
US9149440B2 (en) * 2003-09-02 2015-10-06 University Of South Florida Nanoparticles for drug-delivery
WO2006002365A2 (en) * 2004-06-24 2006-01-05 Angiotech International Ag Microparticles with high loadings of a bioactive agent
US20060205733A1 (en) 2004-08-26 2006-09-14 Encysive Pharmaceuticals Endothelin a receptor antagonists in combination with phosphodiesterase 5 inhibitors and uses thereof
US8034762B2 (en) * 2004-09-02 2011-10-11 Cognosci, Inc. Treatment of subarachnoid hemorrhage with Apo E analogs
WO2006084005A2 (en) 2005-02-02 2006-08-10 University Of Vermont And State Agricultural College Emergence of a r-type ca2+channel(cav2.3) contributes to cerebral artery constriction following subarachnoid hemorrhage
EP2500031A3 (en) 2005-02-24 2012-12-26 Joslin Diabetes Center, Inc. Compositions and Methods for Treating Vascular Permeability
US20060217340A1 (en) 2005-03-23 2006-09-28 University Of Vermont And State Agricultural College Methods and products for treating hypertension by modulation of TRPC3 channel activity
EP1865924B1 (en) * 2005-03-31 2015-12-09 Lidds Ab Method for treating prostate diseases based on local delivery of active substances
EP1893230A2 (en) 2005-04-26 2008-03-05 Maxygen Holdings Ltd. Use of modified factor vii for treating bleeding
EP1883465B1 (fr) * 2005-05-24 2010-01-20 Utéron Pharma S.A. Dispositif de melange a double chambre pour substances pharmaceutiques visqueuses et procede
WO2006133045A1 (en) * 2005-06-03 2006-12-14 Elan Pharma International, Limited Nanoparticulate benidipine compositions
JP2009501188A (ja) 2005-07-15 2009-01-15 ノボ ノルディスク ヘルス ケア アーゲー 抗血小板療法で治療される患者における脳内出血（ＩＣＨ）後の出血増大及び／又は浮腫形成を予防又は軽減するための第ＶＩＩａ因子又は第ＶＩＩａ因子等価物の使用
JP2009516751A (ja) * 2005-11-21 2009-04-23 ザ・ボード・オブ・トラスティーズ・オブ・ザ・ユニバーシティー・オブ・アラバマ・フォー・アンド・オン・ビハーフ・オブ・ザ・ユニバーシティー・オブ・アラバマ 神経保護のための小分子化合物を使用する方法
US9005183B2 (en) * 2007-05-16 2015-04-14 Health Knight, Llc System and method for treating erectile dysfunction
KR101554250B1 (ko) * 2007-06-11 2015-09-18 알. 로치 맥도날드 뇌혈관 연축의 예방을 위한 약물 전달 시스템
US10092524B2 (en) 2008-06-11 2018-10-09 Edge Therapeutics, Inc. Compositions and their use to treat complications of aneurysmal subarachnoid hemorrhage
JP5502751B2 (ja) 2007-12-20 2014-05-28 エボニック コーポレイション 低残留溶媒濃度を有する微粒子を調製するためのプロセス
JP2009067771A (ja) * 2008-05-27 2009-04-02 Pacira Pharmaceuticals Inc 神経学的疾患の治療方法
US20100008968A1 (en) 2008-06-26 2010-01-14 Lampe John W Method for treating cardiovascular diseases using rho kinase inhibitor compounds
EP2331082B1 (en) 2008-09-11 2021-01-06 Evonik Corporation Solvent extraction microencapsulation with tunable extraction rates
EP2334288B1 (en) 2008-09-18 2021-05-19 Evonik Corporation Microencapsulation process with solvent and salt
US20100216948A1 (en) 2009-01-23 2010-08-26 Tipton Arthur J Polymer mixtures comprising polymers having different non-repeating units and methods for making and using same
US20130059008A1 (en) 2009-01-23 2013-03-07 Jeffrey L. Atkinson Drying methods for tuning microparticle properties
WO2010085609A2 (en) 2009-01-23 2010-07-29 Surmodics Pharmaceuticals, Inc. Controlled release systems from polymer blends
US20100291027A1 (en) 2009-05-14 2010-11-18 Jason Campbell Hyaluronic acid (ha) injection vehicle
US20110033463A1 (en) * 2009-08-06 2011-02-10 Medtronic, Inc. Apheresis, administration of agent, or combination thereof
WO2011087689A2 (en) 2009-12-22 2011-07-21 Surmodics Pharmaceuticals,Inc. Emulsion-based process for preparing microparticles and workhead assembly for use with same
GB2490084A (en) 2010-02-22 2012-10-17 Edge Therapeutics Inc Methods and compositions to treat hemorrhagic conditions of the brain
US9504643B2 (en) 2010-03-29 2016-11-29 Evonik Corporation Compositions and methods for improved retention of a pharmaceutical composition at a local administration site
JP5900805B2 (ja) * 2011-01-27 2016-04-06 エルジー・ケム・リミテッド 間隙充填用スウェリングテープ
SG10201602665UA (en) * 2011-04-05 2016-05-30 Edge Therapeutics Intraventricular Drug Delivery System For Improving Outcome After A Brain Injury Affecting Cerebral Blood Flow

Also Published As

Publication number Publication date
RU2016144847A (ru) 2018-05-17
KR20140052992A (ko) 2014-05-07
CN103517726B (zh) 2016-08-17
NZ616458A (en) 2016-01-29
SG193991A1 (en) 2013-11-29
HK1198933A1 (en) 2015-06-19
RU2016144847A3 (enExample) 2018-05-17
AU2012240131B2 (en) 2017-07-20
GB2513675A (en) 2014-11-05
CA2832501A1 (en) 2012-10-11
AU2012240131A1 (en) 2013-10-17
JP2014515744A (ja) 2014-07-03
JP2017036320A (ja) 2017-02-16
EP2694133A1 (en) 2014-02-12
NZ714032A (en) 2017-03-31
US9364432B2 (en) 2016-06-14
RU2606169C2 (ru) 2017-01-10
US20120245561A1 (en) 2012-09-27
RU2013148938A (ru) 2015-05-10
EP2694133A4 (en) 2014-11-19
IL228539B (en) 2018-10-31
CN103517726A (zh) 2014-01-15
NZ727856A (en) 2018-06-29
WO2012138854A1 (en) 2012-10-11
IL228539A0 (en) 2013-12-31
SG10201602665UA (en) 2016-05-30
US20160193198A1 (en) 2016-07-07
EP2694133B1 (en) 2018-05-23
GB201317446D0 (en) 2013-11-13

Similar Documents

Publication Publication Date Title
JP6336899B2 (ja) 脳血流に影響する脳損傷後の結果を改善するための脳室内ドラッグデリバリーシステム
JP5576790B2 (ja) 脳血管れん縮の予防用薬物送達システム
JP6146814B2 (ja) クモ膜下出血のヒトの予後を改善する組成物及び方法
CA2826890A1 (en) Compositions and methods for improving prognosis of a human with subarachnoid hemorrhage
HK1230079A1 (en) Compositions and methods for improving prognosis of a human with subarachnoid hemorrhage
NZ727856B2 (en) Intraventricular drug delivery system for improving outcome after a brain injury affecting cerebral blood flow
NZ616458B2 (en) Intraventricular drug delivery system for improving outcome after a brain injury affecting cerebral blood flow
NZ613970B2 (en) Compositions and methods for improving prognosis of a human with subarachnoid hemorrhage
NZ714032B2 (en) Intraventricular drug delivery system for improving outcome after a brain injury affecting cerebral blood flow

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150406

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150406

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160217

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20160517

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20160620

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20161020

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20161130

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20170217

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20170331

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171003

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180123

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180507

R150 Certificate of patent or registration of utility model

Ref document number: 6336899

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees